Search

Now showing items 1-1 of 1

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

O'Driscoll, Lorraine; Eustace, Alex J.; Conlon, Neil T.; McDermott, Martina S.J.; Browne, Brigid C.; O'Leary, Patrick; Holmes, Frankie A.; Espina, Virginia; Liotta, Lance A.; O'Shaughnessy, Joyce; Gallagher, Clair; Rani, Sweta; Madden, Stephen F.; O'Brien, Neil A.; Ginther, Charles; Slamon, Dennis; Walsh, Naomi; Gallagher, William M.; Zagozdzon, Radoslaw; Watson, William R.; O'Donovan, Norma; Crown, John (2018)

Browse

All of TARA

This Academic/Research Unit

Discover

Author

Subject

Date Issued

Sponsor

Search

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Browse

All of TARA

This Academic/Research Unit

Discover

Author

Subject

Date Issued

Sponsor

Search

Advanced Search

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.